TD Cowen Reaffirms Their Buy Rating on BioCryst (BCRX)
TD Cowen analyst Stacy Ku maintained a Buy rating on BioCryst today and set a price target of $30.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Ku is a 4-star analyst with an average return of 14.2% and a 62.71% success rate. Ku covers the Healthcare sector, focusing on stocks such as BioCryst, UCB SA, and LENZ Therapeutics.
In addition to TD Cowen, BioCryst also received a Buy from Wedbush’s Laura Chico in a report issued on December 18. However, on December 17, Evercore ISI reiterated a Hold rating on BioCryst (NASDAQ: BCRX).
Based on BioCryst’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $159.4 million and a net profit of $12.9 million. In comparison, last year the company earned a revenue of $117.09 million and had a GAAP net loss of $14.03 million
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year. Earlier this month, Alane Barnes, the CLO of BCRX sold 50,906.00 shares for a total of $367,032.26.
Read More on BCRX:
Disclaimer & DisclosureReport an Issue
- BioCryst’s Orladeyo Pediatric Approval and Strategic Expansion Drive Buy Rating
- BioCryst price target raised to $32 from $30 at H.C. Wainwright
- BioCryst’s Avoralstat Study: A New Hope for Diabetic Macular Edema?
- Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy’ Stocks
- BioCryst’s Growth Potential Bolstered by FDA Approval and Strategic Moves: A Buy Recommendation
